Equity Overview
Price & Market Data
Price: $1.46
Daily Change: +$0.0464 / 3.18%
Range: $1.36 - $1.75
Market Cap: $14,853,748
Volume: 33,901
Performance Metrics
1 Week: 11.45%
1 Month: -1.35%
3 Months: -29.94%
6 Months: -30.48%
1 Year: -3.95%
YTD: -27.72%
Company Details
Employees: 11
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.